Subtherapeutic itraconazole and voriconazole levels in children with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 12, Issue 4, 2013, Pages 418-419

  Bentley, S ^a   Gupta, A ^a   Balfour Lynn, I M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROSPECTIVE STUDY; SCHOOL CHILD; THERAPY EFFECT;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CYSTIC FIBROSIS; HUMANS; ITRACONAZOLE; PROSPECTIVE STUDIES; PYRIMIDINES; TRIAZOLES;

EID: 84878364537     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.09.007     Document Type: Letter

References (5)

1. Stevens D.A., Moss R.B., Kurup V.P., Knutsen A.P., Greenberger P., Judson M.A., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. CID 2003, 37(Suppl. 3):S225-S264.
2. Cystic Fibrosis Trust Antibiotic treatment for cystic fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group May 2009, Available on http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/Antibiotic_treatment_for_Cystic_Fibrosis.pdf (accessed June 2012). 3rd ed.
3. Conway S.P., Etherington C., Peckham D.G., Brownlee K.G., Whitehead A., Cunliffe H. Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. J Antimicrob Chemother 2004, 53:841-847.
4. Rey E., Treluyer J.M., Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998, 35(4):313-329.
5. Aaron S.D., Vandemheen K.L., Freitag A., Pedder L., Cameron W., Lavoie A., et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One 2012, 7:e36077.